Report Detail
Europe Vaccines Market to 2027- Regional Analysis and Forecasts By Technology (Recombinant Vaccines, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated and Subunit Vaccines, and Toxoid Vaccines); Disease Indication (DTP (Diphtheria Tetanus toxoids and Pertussis), Influenza, Hepatitis, Respiratory Syncytial Virus (RSV), and Other Diseases); Route of Administration (Oral, Injectable, and Other Routes of Administration); Patient Type (Pediatric Patients, and Adult Patients), and Country
- RnM3599563 |
- 16 July, 2019 |
- Global |
- 154 Pages |
- The Insight Partners |
- Pharma & Healthcare
The Europe Vaccines Market is expected to reach US$ 16,291.0 Mn in 2027 from US$ 9,576.2 Mn in 2018. The market is estimated to grow with a CAGR of 5.5% from 2019-2027.
Vaccination saves lives and improves quality of life. For instance, Polio is an infectious disease caused by poliovirus and causes muscle weakness that results in the inability to move, which further hampers the quality of life. Polio vaccine protects an individual against polio. The vaccine produces antibodies in the bloodstream against the poliovirus. Due to the strong promotion of Polio vaccine in Europe, the World Health Organization in 2002, declared the European Region polio-free.
The countries in the European region are joining forces to eradicate infectious diseases like measles, diphtheria, rubella, pertussis, and others through vaccinations. There are several vaccination programs, campaigns, conferences, being held in the European region in order to raise awareness among the population. For instance, European Immunization Week (EIW) is renowned across the European Region and is celebrated every April to raise awareness of the importance of vaccination for people’s health and well-being. European Centre for Disease Prevention and Control (ECDC) supports the European Immunization Week campaign undertook by WHO/Europe and provides scientific evidence on vaccination.
Furthermore, 38th Euro Global Summit and Expo on Vaccines & Vaccination will be held in June 2020 Frankfurt, Germany. The conference focuses on discussing novel strategies in vaccines and immunology research. The aim of the conference is to encourage quality research and to bring together the world-class researchers, international communities, and industrial heads to discuss the new developments and innovations in the fields of vaccines and immunology.
In 2018, the conjugate vaccines segment held the largest market share of 27.6% of the vaccines market, by type. This segment is also expected to dominate the market in 2027 owing to the advantages offered by the vaccines for diseases such as pneumonia and others. Furthermore, the conjugate vaccines segment is anticipated to witness the significant growth rate during the forecast period, 2019 to 2027.
Europe Vaccines Market by the disease indication was led by the other segments, which has included diseases such as poliomyelitis (polio), measles, mumps, rubella, pneumococcal infections, and others. The other segment has the largest market share in 2018, which accounted for 59.8% and is expected to dominate the market in 2027. Similarly, the vaccines market by the route of administration was led by the injectable segment. Whereas, the market of the vaccines in Europe by the patient type was led by the pediatric segment.
Some of the major primary and secondary sources for vaccines included in the report are Immunization Partners in Europe (IPAP), Food and Drug Administration, World Health Organization, National Polio Surveillance Project (NPSP), European Health Management Association (EHMA), European Centre for Disease Prevention and Control (ECDC), European Immunization Week (EIW) and Others.
1. Introduction
- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance
2. Europe Vaccines Market – Key Takeaways
3. Europe Vaccines Market – Market Landscape
- 3.1 overview
- 3.2 Market Segmentation
- 3.2.1 Europe Vaccines Market – By Technology
- 3.2.2 Europe Market – By Disease Indication
- 3.2.3 Europe Vaccines Market – By Route of Administration
- 3.2.4 Europe Vaccines Market – By Patient Type
- 3.2.5 Europe Vaccines Market – By Country
- 3.3 PEST Analysis
4. Europe Vaccines Market - Key Market Dynamics
- 4.1 Key Market Drivers
- 4.1.1 Growing Awareness Programs for Vaccination in Europe
- 4.1.2 Increasing Vaccines Research and Development Activities in Europe.
- 4.2 Key Market Restraints
- 4.2.1 Vaccines Hesitancy in the European region.
- 4.3 Key Market Opportunities
- 4.3.1 Growing Prevalence of Infectious Diseases
- 4.4 Future Trends
- 4.4.1 New Vaccines In Development
- 4.5 Impact Analysis
5. Vaccines Market – Europe Analysis
- 5.1 Europe Vaccines Market Revenue Forecasts and Analysis
- 5.2 Market Positioning
- 5.3 Performance of Key Players
- 5.3.1 Sanofi
6. Europe Vaccines Market Analysis – By Technology
- 6.1 Overview
- 6.2 Europe Vaccines Market, By Type, 2018 & 2027 (%)
- 6.3 Europe Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
- 6.4 Europe Recombinant Vaccines Market
- 6.4.1 Overview
- 6.4.2 Europe Recombinant Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
- 6.5 Europe Conjugate Vaccines Market
- 6.5.1 Overview
- 6.5.2 Europe Conjugate Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
- 6.6 Europe Live Attenuated Vaccines Market
- 6.6.1 Overview
- 6.6.2 Europe Live Attenuated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
- 6.7 Europe Inactivated Vaccines Market
- 6.7.1 Overview
- 6.7.2 Europe Inactivated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
- 6.8 Europe Toxoid Vaccines Market
- 6.8.1 Overview
- 6.8.2 Europe Toxoid Vaccines Market Revenue and Forecast to 2027 (US$ Mn)
7. Europe Vaccines Market Analysis – By Disease Indication
- 7.1 Overview
- 7.2 Europe Vaccines Market, By Disease Indication, 2018 & 2027 (%)
- 7.3 Europe Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
- 7.4 Europe DTP (Diphtheria, Tetanus, And Pertussis) Market
- 7.4.1 Overview
- 7.4.2 Europe DTP (Diphtheria, Tetanus, And Pertussis) Market Revenue and Forecast to 2027 (US$ Mn)
- 7.5 Europe Influenza Market
- 7.5.1 Overview
- 7.5.2 Europe Influenza Market Revenue and Forecast to 2027 (US$ Mn)
- 7.6 Europe Hepatitis Market
- 7.6.1 Overview
- 7.6.2 Europe Hepatitis Market Revenue and Forecast to 2027 (US$ Mn)
- 7.7 Europe Other Diseases Market
- 7.7.1 Overview
- 7.7.2 Europe Other Diseases Market Revenue and Forecast to 2027 (US$ Mn)
8. Europe Vaccines Market Analysis – By Route of Administration
- 8.1 Overview
- 8.2 Europe Vaccines Market, By Route of Administration, 2018 & 2027 (%)
- 8.3 Europe Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
- 8.4 Europe Oral Market
- 8.4.1 Overview
- 8.4.2 Europe Oral Market Revenue and Forecast to 2027 (US$ Mn)
- 8.5 Europe Injectable Market
- 8.5.1 Overview
- 8.5.2 Europe Injectable Market Revenue and Forecast to 2027 (US$ Mn)
- 8.6 Europe Other Routes of Administration Market
- 8.6.1 Overview
- 8.6.2 Europe Other Routes of Administration Market Revenue and Forecast to 2027 (US$ Mn)
9. Europe Vaccines Market Analysis – By Patient Type
- 9.1 Overview
- 9.2 Europe Vaccines Market, By Patient Type, 2018 & 2027 (%)
- 9.3 Europe Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
- 9.4 Europe Pediatric Market
- 9.4.1 Overview
- 9.4.2 Europe Pediatric Market Revenue and Forecast to 2027 (US$ Mn)
- 9.5 Europe Adults Market
- 9.5.1 Overview
- 9.5.2 Europe Adults Market Revenue and Forecast to 2027 (US$ Mn)
10. Europe Vaccines Market Revenue And Forecasts To 2027
- 10.1.1 Europe Vaccines Market Revenue Overview, by Country (2017) (US$ Mn)
- 10.1.2 Europe Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.3 Europe Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
- 10.1.4 Europe Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
- 10.1.5 Europe Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
- 10.1.6 Europe Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
- 10.1.7 Europe Vaccines Market Revenue and Forecasts to 2027, By Country (%)
- 10.1.8 Germany Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.9 Germany Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.9.1 Germany Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
- 10.1.9.2 Germany Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
- 10.1.9.3 Germany Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
- 10.1.9.4 Germany Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
- 10.1.10 UK Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.11 UK Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.11.1 UK Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
- 10.1.11.2 UK Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
- 10.1.11.3 UK Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
- 10.1.11.4 UK Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
- 10.1.12 France Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.13 France Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.13.1 France Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
- 10.1.13.2 France Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
- 10.1.13.3 France Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
- 10.1.13.4 France Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
- 10.1.14 Italy Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.15 Italy Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.15.1 Italy Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
- 10.1.15.2 Italy Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
- 10.1.15.3 Italy Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
- 10.1.15.4 Italy Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
- 10.1.16 Spain Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.17 Spain Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
- 10.1.17.1 Spain Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)
- 10.1.17.2 Spain Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)
- 10.1.17.3 Spain Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)
- 10.1.17.4 Spain Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)
11. Vaccines Market –Industry Landscape
- 11.1 Overview
- 11.2 Comparative Company Analysis
- 11.3 Growth Strategies Done by the Companies in the Market, (%)
- 11.4 Organic Developments
- 11.4.1 Overview
- 11.5 Inorganic Developments
- 11.5.1 Overview
12. Vaccines Market–Key Company Profiles
- 12.1 Pfizer Inc.
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Financial Overview
- 12.1.4 Product Portfolio
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 GlaxoSmithKline plc.
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Financial Overview
- 12.2.4 Product Portfolio
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 Merck & Co., Inc.
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Financial Overview
- 12.3.4 Product Portfolio
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 Sanofi
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Financial Information
- 12.4.4 Product Portfolio
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 Johnson & Johnson Services, Inc.
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Financial Overview
- 12.5.4 Product Portfolio
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 Panacea Biotic Limited
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Financial Information
- 12.6.4 Product Portfolio
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 Astellas Pharma Inc.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Financial Overview
- 12.7.4 Product Portfolio
- 12.7.5 Swot Analysis
- 12.7.6 Key Developments
- 12.8 NOVAVAX, INC.
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Financial Information
- 12.8.4 Product Pipeline
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 VBI Vaccines Inc.
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Financial Information
- 12.9.4 Product Portfolio
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
- 12.10 BAVARIAN NORDIC
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Financial Information
- 12.10.4 Product Pipeline
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
13. Appendix
- 13.1 About The Insight Partners
- 13.2 Glossary of Terms
- 13.3 Methodology
- 13.3.1 Coverage
- 13.3.2 Secondary Research
Summary:
Get latest Market Research Reports on Europe Vaccines . Industry analysis & Market Report on Europe Vaccines is a syndicated market report, published as Europe Vaccines Market to 2027- Regional Analysis and Forecasts By Technology (Recombinant Vaccines, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated and Subunit Vaccines, and Toxoid Vaccines); Disease Indication (DTP (Diphtheria Tetanus toxoids and Pertussis), Influenza, Hepatitis, Respiratory Syncytial Virus (RSV), and Other Diseases); Route of Administration (Oral, Injectable, and Other Routes of Administration); Patient Type (Pediatric Patients, and Adult Patients), and Country. It is complete Research Study and Industry Analysis of Europe Vaccines market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
